Supplementary Methods and Synthesis of RED-106 from CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models
- Resource Type
- Source
- Subject
- Language